Table 1 Clinical characteristics of the study cohort.
Patients undergoing TIPS | |
|---|---|
Number of patients (n) | 141 |
Age (years, median and IQR) | 60 (24–84) |
Sex, n (%) | |
Female | 31 (22.0) |
Male | 110 (78.0) |
TIPS indication, n (%) | |
Ascites | 120 (85) |
Bleeding | 21 (15) |
Etiology, n (%) | |
ALD | 111 (78.7) |
MASLD | 11 (7.8) |
Cholestatic | 4 (2.8) |
Viral | 2 (1.4) |
Other | 13 (9.2) |
Child–Pugh, n (%) | |
A | 9 (6.4) |
B | 93 (66.0) |
C | 39 (27.7) |
Sodium (mmol/L, median and IQR) | 135 (122–144) |
Creatinine (mg/dL, median and IQR) | 0.93 (0.39–7.17) |
Bilirubin (mg/dL, median and IQR) | 2.0 (0.4–6.98) |
Albumin (g/dL, median and IQR) | 2.9 (1.8–4.0) |
INR (mmol/L, median and IQR) | 1.3 (1.0–3.5) |
Platelets (× 1000/µL, median and IQR) | 145 (17–455) |
ALT (U/L, median and IQR) | 38 (9–437) |
WBC (× 1000/µL, median and IQR) | 6.4 (1.0–25.3) |
CRP (mg/L, median and IQR) | 12.8 (0.3–146.9) |
Soluble urokinase plasminogen activator receptor (suPAR) (ng/mL, median and IQR) | 8.8 (6.5–11.2) |
